Scholarlink

<p>The development of bedaquiline holds promise for treating multidrug-resistant tuberculosis (MDR-TB). Still, the inflation in bedaquiline resistance has alarmed the global public health crisis, indicating the need for a new treatment strategy. Several scientific studies have reported a high incidence of resistance among MDR-TB patients who had prior exposure to bedaquiline for treating <i>Mycobacterium tuberculosis</i> infections. Disparate research findings indicate that individuals previously administered this drug exhibit a remarkable prevalence of resistance. Studies have further demonstrated that prior treatment often correlates with the emergence of resistant <i>Mycobacterium tuberculosis</i> strains. Overall, evidence from multiple investigations highlights a concerning trend of increased resistance in MDR-TB cases with a history of bedaquiline therapy. Moreover, bedaquiline resistance in MDR-TB strains has been linked to mutations in several chromosomal genes, including <i>atpE</i>, <i>Rv0677c</i>, <i>Rv0678</i>, and <i>pepQ</i>. Consequently, it is imperative to mitigate the burden of MDR-TB and bedaquiline resistance. Herein, this article emphasizes structural features, mechanism of action, emergence of underlying resistance mechanisms, pharmacokinetic &amp; pharmacodynamic properties, clinical toxicity, and strategies to combat resistance associated with bedaquiline.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bedaquiline Resistance: A Looming Global Threat in Tuberculosis Management

  • 期刊论文

  • 发表日期：

    2025年12月9日

查看全文
  • Indu Singh,
  • Juhi Sharma,
  • Divakar Sharma,
  • Arun Ratn,
  • Deepa Bisht,
  • Sandeep Sharma,
  • Megh Singh Dhakad,
  • Jasbir Dalal,
  • Mirza Masroor Ali Beg

摘要

The development of bedaquiline holds promise for treating multidrug-resistant tuberculosis (MDR-TB). Still, the inflation in bedaquiline resistance has alarmed the global public health crisis, indicating the need for a new treatment strategy. Several scientific studies have reported a high incidence of resistance among MDR-TB patients who had prior exposure to bedaquiline for treating Mycobacterium tuberculosis infections. Disparate research findings indicate that individuals previously administered this drug exhibit a remarkable prevalence of resistance. Studies have further demonstrated that prior treatment often correlates with the emergence of resistant Mycobacterium tuberculosis strains. Overall, evidence from multiple investigations highlights a concerning trend of increased resistance in MDR-TB cases with a history of bedaquiline therapy. Moreover, bedaquiline resistance in MDR-TB strains has been linked to mutations in several chromosomal genes, including atpE, Rv0677c, Rv0678, and pepQ. Consequently, it is imperative to mitigate the burden of MDR-TB and bedaquiline resistance. Herein, this article emphasizes structural features, mechanism of action, emergence of underlying resistance mechanisms, pharmacokinetic & pharmacodynamic properties, clinical toxicity, and strategies to combat resistance associated with bedaquiline.